The Significance of Defensin Alpha 4 in the Pathophysiology of the Adrenal Insufficiency in Inflammatory Lung Diseases
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients 18-80 yo
- Patients diagnosed with pneumonia or exacerbated COPD
- Healthy controls 18-80yo
- Signed informed consent
Exclusion Criteria:
- Pregnant or lactating females
- Life threatening severe disease
- Known primary or secondary adrenal insufficiency
- Systemic steroid therapy in the last 8 weeks
- Systemic therapy with opioid
- Systemic therapy with Ketoconazol, Mitotane, Metopyron, Etomidat, Rifampicin
- In healthy controls: relevant respiratory disease or known adrenal insufficiency or indication of infection
- Allergic reaction to ACTH
- Missing informed consent
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KSSG-Pneumo-0001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.